Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Gastroesophageal Reflux 1

Interventions

Oxaliplatin 290Capecitabine 206Fluorouracil 181Cisplatin 168Docetaxel 138S 1 (combination) 132Paclitaxel 121Leucovorin 116Irinotecan 106pembrolizumab 103Trastuzumab 72apatinib 56Nivolumab 56sintilimab 45Drug Therapy 43Surgical Procedures, Operative 37Radiotherapy 37Bevacizumab 37Ramucirumab 34titanium silicide 31Hyperthermic Intraperitoneal Chemotherapy 30Epirubicin 30Carboplatin 30tislelizumab 28Cyclophosphamide 27XELOX 24Tegafur 23Folfox protocol 22Albumin-Bound Paclitaxel 22camrelizumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Stomach Neoplasms × ilaprazole × Clear all
NCT02638584 2020-07-31

Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.

Il-Yang Pharm. Co., Ltd.

Phase 4 Completed
176 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡